Personalis/$PSNL
1D1W1MYTD1Y5YMAX
Capital at risk
About Personalis
Personalis Inc is a provider of genomic sequencing and analytics solutions to support the development of personalized cancer vaccines and other next-generation cancer immunotherapies. It has one segment, the sale of sequencing and data analysis services. The company' products include ImmunoID NeXT, NeXT Personal, NeXT Dx Test, and other pharma research solutions.
- Ticker
- $PSNL
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 260
- Headquarters
- Fremont, United States
- Website
- www.personalis.com
Personalis Metrics
BasicAdvanced
$1.7B
-
-$1.10
2.28
-
Price and volume
Market cap
$1.7B
Beta
2.28
52-week high
$18.89
52-week low
$4.96
Average daily volume
3.3M
Financial strength
Current ratio
5.283
Quick ratio
4.91
Long term debt to equity
12.828
Total debt to equity
16.157
Interest coverage (TTM)
-536.66%
Profitability
EBITDA (TTM)
-104.596
Gross margin (TTM)
12.69%
Net profit margin (TTM)
-153.84%
Operating margin (TTM)
-164.07%
Effective tax rate (TTM)
-0.03%
Revenue per employee (TTM)
$270,000
Management effectiveness
Return on assets (TTM)
-25.03%
Return on equity (TTM)
-50.32%
Valuation
Price to revenue (TTM)
22.72
Price to book
7.33
Price to tangible book (TTM)
7.33
Price to free cash flow (TTM)
-15.676
Free cash flow yield (TTM)
-6.38%
Free cash flow per share (TTM)
-1.034
Growth
Revenue change (TTM)
-13.26%
Earnings per share change (TTM)
-6.88%
3-year revenue growth (CAGR)
1.24%
3-year earnings per share growth (CAGR)
-22.55%
What the Analysts think about Personalis
Analyst ratings (Buy, Hold, Sell) for Personalis stock.
Analyst projections of the future price of Personalis stock.
Bulls say / Bears say
In Q2 2026, Personalis’ clinical test volume grew 199% year-over-year to 10,384 tests, driving clinical revenue up 442% to $2.6 million. (SEC filing)
The company secured Medicare coverage approvals in Q2 2026 for immunotherapy (IO) monitoring and neoadjuvant breast cancer monitoring, expanding reimbursement to four indications. (SEC filing)
Tempus AI agreed on July 20, 2026 to acquire Personalis for $16.25 per share, valuing the company at $1.5 billion and providing a strategic premium. (Reuters)
Personalis reported a net loss of $31.7 million in Q2 2026, compared with a loss of $20.1 million in Q2 2025, highlighting ongoing unprofitability. (SEC filing)
Revenue from population sequencing (the VA MVP) fell 9% year-over-year to $3.0 million in Q2 2026, signaling volatility in this key segment. (SEC filing)
Following the July 20, 2026 merger announcement with Tempus AI, Personalis will cease providing financial guidance and quarterly earnings calls, reducing transparency for investors. (SEC filing)
Data summarised monthly by Lightyear AI. Last updated on 23 Aug 2026.
Personalis Financial Performance
Revenues and expenses
Personalis Earnings Performance
Company profitability
Upcoming events
No upcoming events
Personalis News
AllArticlesVideos
Personalis Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Personalis, Inc. - PSNL
Business Wire2 months ago
Tempus AI Makes Billion-Dollar Bet on the Future of Cancer Monitoring
Benzinga2 months ago
PSNL Stock Alert: Halper Sadeh LLC is Investigating Whether Personalis, Inc. is Obtaining a Fair Price for Shareholders
Business Wire2 months ago
Funds containing Personalis
AllUSDGBPEUR
Fund name | Fund size | $PSNL weighting |
|---|---|---|
iShares Nasdaq US Biotechnology$BTEC | $1.2B | 0.09% |
iShares Nasdaq US Biotechnology£BTEK | £865M | 0.09% |
SPDR Russell 2000 US Small Cap€R2US | €4.8B | 0.04% |
iShares MSCI World Small Cap$WSML | $9B | 0.01% |
iShares MSCI World Small Cap€IUSN | €7.8B | 0.01% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.